NCT04143061View on ClinicalTrials.gov

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa

PHASE3CompletedINTERVENTIONAL
Enrollment

1,328

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

January 28, 2023

Study Completion Date

January 28, 2023

Conditions
Meningococcal ImmunizationHealthy Volunteers
Interventions
BIOLOGICAL

Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine

Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL

BIOLOGICAL

Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine

Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL

BIOLOGICAL

Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine

Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL

Trial Locations (17)

1055

Investigational Site Number : 7100001, Middelburg

1818

Investigational Site Number : 7100003, Soweto

2013

Investigational Site Number : 7100004, Bertsham

7505

Investigational Site Number : 7100005, Cape Town

7937

Investigational Site Number : 7100002, Cape Town

9301

Investigational Site Number : 7100007, Bloemfontein

141008

Investigational Site Number : 3560010, Punjab

411011

Investigational Site Number : 3560003, Pune

411043

Investigational Site Number : 3560008, Pune

500018

Investigational Site Number : 3560004, Hyderabad

560054

Investigational Site Number : 3560002, Bangalore

570004

Investigational Site Number : 3560012, Mysore

590002

Investigational Site Number : 3560016, Belagavi

603203

Investigational Site Number : 3560007, Chennai

700017

Investigational Site Number : 3560011, Kolkata

751003

Investigational Site Number : 3560015, Odisha

0002

Investigational Site Number : 7100006, Pretoria

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04143061 - Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa | Biotech Hunter | Biotech Hunter